Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Clinical protocols

On-demand prophylaxis protects against HIV infection in at-risk men

Randomised trial shows pre-exposure prophylaxis reduced the risk of HIV transmission by 86%.

Research found that pre-exposure prophylaxis, taken at the time of sexual activity, reduced the risk of HIV transmission by 86% compared with placebo among men who have sex with men. In the image, close up of Truveda pill used for pre-exposure prophylaxis

Source: Shutterstock.com

Truvada (tenofovir disoproxil fumarate combined with emtricitabine), taken at the time of sexual activity, reduced the risk of HIV transmission by 86% in men who have sex with men 

Pre-exposure prophylaxis is a potential intervention that could reduce the transmission of HIV to people at high risk, such as men who have sex with men (MSM). However, studies have returned conflicting results, possibly due to low adherence to a daily regimen. 

Research published in the New England Journal of Medicine (online 3 December 2015)[1] has found that taking tenofovir disoproxil fumarate combined with emtricitabine at the time of sexual activity, reduced the risk of HIV transmission by 86% compared with placebo among MSM. 

During a median follow-up of 9.3 months, two (1.0%) of 199 men randomised to prophylaxis became infected with HIV-1 compared with 14 (7.0%) of 201 men in the placebo group. 

The researchers, from France and Canada, say the findings support the use of prophylaxis for men at high-risk of HIV transmission. 

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2015.20200222

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Research found that pre-exposure prophylaxis, taken at the time of sexual activity, reduced the risk of HIV transmission by 86% compared with placebo among men who have sex with men. In the image, close up of Truveda pill used for pre-exposure prophylaxis

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.